CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE- clindamycin phosphate, benzoyl peroxide gel
Perrigo New York Inc

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CLINDAMYCIN PHOSPHATE and BENZOYL PEROXIDE GEL safely and effectively. See full prescribing information for CLINDAMYCIN PHOSPHATE and BENZOYL PEROXIDE GEL.

CLINDAMYCIN PHOSPHATE and BENZOYL PEROXIDE gel, 1.2%/2.5%, for topical use
Initial U.S. Approval: 2000

INDICATIONS AND USAGE
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. (1)

DOSAGE AND ADMINISTRATION

• Apply a pea-sized amount of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the face once daily. (2)
• Not for oral, ophthalmic, or intravaginal use. (2)

DOSAGE FORMS AND STRENGTHS
Gel, 1.2% clindamycin phosphate/2.5% benzoyl peroxide (3)

CONTRAINDICATIONS
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is contraindicated in:

• Patients who have demonstrated hypersensitivity (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. (4.1)
• Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. (4.2)

WARNINGS AND PRECAUTIONS

• Colitis: Orally and parenterally administered clindamycin has been associated with severe colitis, which may result in death. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% should be discontinued if significant diarrhea occurs. (5.1)
• Ultraviolet Light and Environmental Exposure: Minimize sun exposure following drug application. (5.2)

ADVERSE REACTIONS
The following selected adverse reactions occurred in less than 0.2% of patients: application site pain (0.1%); application site exfoliation (0.1%); and application site irritation (0.1%). (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS
Avoid using Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% in combination with topical or oral erythromycin-containing products because of its clindamycin component. (7.1)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 7/2020

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
4.1 Hypersensitivity
4.2 Colitis/Enteritis

5 WARNINGS AND PRECAUTIONS
5.1 Colitis
5.2 Ultraviolet Light and Environmental Exposure
5.3 Concomitant Topical Medications

6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience

7 DRUG INTERACTIONS
7.1 Erythromycin
7.2 Neuromuscular Blocking Agents

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.3 Pharmacokinetics
12.4 Microbiology

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
16.2 Dispensing Instructions for the Pharmacist
16.3 Storage and Handling

17 PATIENT COUNSELING INFORMATION
* Sections or subsections omitted from the full prescribing information are not listed.

---

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is indicated for the topical treatment of acne vulgaris in patients 12 years or older.

2 DOSAGE AND ADMINISTRATION
Before applying Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, wash your face gently with a mild soap, rinse with warm water, and pat your skin dry. Apply a pea-sized amount of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the face once daily. Avoid the eyes, mouth, mucous membranes, or areas of broken skin.

Use of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% beyond 12 weeks has not been evaluated.

Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy
effect may occur, especially with the use of peeling, desquamating, or abrasive agents.

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is not for oral, ophthalmic, or intravaginal use.

3 DOSAGE FORMS AND STRENGTHS

Gel, 1.2%/2.5%

Each gram of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% contains 10 mg (1%) clindamycin as phosphate, and 25 mg (2.5%) benzoyl peroxide in a white to off-white, opaque, smooth gel.

4 CONTRAINDICATIONS

4.1 Hypersensitivity

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. Anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5%. [See Postmarketing Experience (6.2).]

4.2 Colitis/Enteritis

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. [See Warnings and Precautions (5.1).]

5 WARNINGS AND PRECAUTIONS

5.1 Colitis

Systemic absorption of clindamycin has been demonstrated following topical use of clindamycin. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. When significant diarrhea occurs, Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% should be discontinued.

Severe colitis has occurred following oral and parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.

Studies indicate toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.

5.2 Ultraviolet Light and Environmental Exposure

Minimize sun exposure including use of tanning beds or sun lamps following drug application.

5.3 Concomitant Topical Medications

Concomitant topical acne therapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritancy or dermatitis occurs, reduce frequency of application or temporarily interrupt treatment and resume once the irritation subsides. Treatment should be discontinued if the irritation persists.
6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions observed in
the clinical trials of a drug cannot always be directly compared to rates in the clinical trials of another
drug and may not reflect the rates observed in practice.

The following selected adverse reactions occurred in less than 0.2% of subjects treated with clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5%: application site pain (0.1%); application site exfoliation (0.1%); and application site irritation (0.1%).

During clinical trials, subjects were assessed for local cutaneous signs and symptoms of erythema, scaling, itching, burning and stinging. Most local skin reactions increased and peaked around Week 4 and continually decreased over time reaching near baseline levels by Week 12. The percentage of subjects that had symptoms present before treatment, the maximum value recorded during treatment, and the percent with symptoms present at Week 12 are shown in Table 1.

Table 1: Percent of Subjects with Local Skin Reactions. Combined Results from the Two Phase 3 Trials (N = 773)

<table>
<thead>
<tr>
<th></th>
<th>Combined Results from the Two Phase 3 Trials (N=773)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before Treatment (Baseline)</td>
</tr>
<tr>
<td></td>
<td>Mild</td>
</tr>
<tr>
<td>Erythema</td>
<td>22</td>
</tr>
<tr>
<td>Scaling</td>
<td>8</td>
</tr>
<tr>
<td>Itching</td>
<td>10</td>
</tr>
<tr>
<td>Burning</td>
<td>3</td>
</tr>
<tr>
<td>Stinging</td>
<td>2</td>
</tr>
</tbody>
</table>

*Mod. = Moderate

6.2 Postmarketing Experience

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Anaphylaxis, as well as allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide.

7 DRUG INTERACTIONS

7.1 Erythromycin

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% should not be used in combination with topical or oral erythromycin-containing products due to its clindamycin component. In vitro studies have shown antagonism between erythromycin and clindamycin. The clinical significance of this in vitro antagonism is not known.

7.2 Neuromuscular Blocking Agents

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, Clindamycin Phosphate and Benzoyl Peroxide Gel,
1.2%/2.5% should be used with caution in patients receiving such agents.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available data on Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. The limited published data on use of clindamycin in pregnant women with exposure during the first trimester are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes (see Data). In limited published clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of major birth defects.

In animal reproduction studies, clindamycin did not cause malformations or embryo-fetal development toxicity in pregnant rats and mice when administered during the period of organogenesis at systemic doses up to 240 times the maximum recommended human dose (MRHD) of 2.5 g Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, based on body surface area (BSA) comparisons (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Human Data

In limited published trials in pregnant women administered clindamycin during the first trimester of pregnancy, there was no difference in the rate of major birth defects reported among in utero exposed infants compared to unexposed infants. These data cannot definitely establish or exclude any clindamycin-associated risk during pregnancy.

Animal Data

Animal reproductive/developmental toxicity studies have not been conducted with Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% or benzoyl peroxide. Developmental toxicity studies of clindamycin performed in pregnant rats and mice administered during the period of organogenesis at oral doses of up to 600 mg/kg/day (240 and 120 times the MRHD for clindamycin, respectively, based on BSA comparisons) or subcutaneous doses of up to 200 mg/kg/day (80 and 40 times the MRHD for clindamycin, respectively, based on BSA comparisons) revealed no malformations or embryo-fetal development toxicity.

8.2 Lactation

Risk Summary

There are no data on the presence of clindamycin or benzoyl peroxide in human milk, the effects on the breastfed child, or the effects on milk production following topical administration. However, clindamycin has been reported to be present in breast milk in small amounts following oral and parenteral administration. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% and any potential adverse effects on the breastfed child from Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% or from the underlying maternal condition.

Clinical Considerations
If used during lactation and Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is applied to the chest, care should be taken to avoid accidental ingestion by the infant.

8.4 Pediatric Use
Safety and effectiveness of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% in pediatric patients under the age of 12 have not been evaluated.

8.5 Geriatric Use
Clinical trials of clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.

11 DESCRIPTION
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is a combination product with two active ingredients in a white to off-white, opaque, smooth, aqueous gel formulation intended for topical use. Clindamycin phosphate is a water-soluble ester of the semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-Dgalacto-octopyranoside 2-(dihydrogen phosphate). The structural formula or clindamycin phosphate is represented below:

Clindamycin phosphate:

Molecular Formula: C_{18}H_{34}ClN_{2}O_{8}PS Molecular Weight: 504.97

Benzoyl peroxide is an antibacterial and keratolytic agent. The structural formula for benzoyl peroxide is represented below:

Benzoyl peroxide:
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% contains the following inactive ingredients: purified water, carbomer 980, propylene glycol, and potassium hydroxide. Each gram of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% contains 1.2% of clindamycin phosphate which is equivalent to 1% clindamycin.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Clindamycin: Clindamycin is a lincosamide antibacterial [See Microbiology (12.4)].

Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action is unknown.

12.3 Pharmacokinetics

The systemic absorption of clindamycin was investigated in an open-label, multiple-dose trial in 16 adult subjects with moderate to severe acne vulgaris treated with 1 gram of clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% applied to the face once daily for 30 days. Twelve subjects (75%) had at least one quantifiable clindamycin plasma concentration above the lower limit of quantification (LOQ = 0.5 ng/mL) on Day 1 or Day 30. On Day 1, the mean (± standard deviation) peak plasma concentration ($C_{\text{max}}$) was $0.78 \pm 0.22$ ng/mL (n=9 with measurable concentrations), and the mean $\text{AUC}_{0-t}$ was $5.29 \pm 0.81$ h.ng/mL (n=4). On Day 30, the mean $C_{\text{max}}$ was $1.22 \pm 0.88$ ng/mL (n=10), and the mean $\text{AUC}_{0-t}$ was $8.42 \pm 6.01$ h.ng/mL (n=6). Clindamycin plasma concentrations were below LOQ in all subjects at 24 hours post-dose on the three tested days (Day 1, 15, and 30).

Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid.

12.4 Microbiology

Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing bacterial protein synthesis.

Clindamycin and benzoyl peroxide individually have been shown to have in vitro activity against *Propionibacterium acnes*, an organism which has been associated with acne vulgaris; however, the clinical significance of this activity against *P. acnes* is not known.

*P. acnes* resistance to clindamycin has been documented. Resistance to clindamycin is often associated with resistance to erythromycin.

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, and impairment of fertility testing of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% have not been performed.

Benzoyl peroxide has been shown to be a tumor promoter and progression agent in a number of animal studies. Benzoyl peroxide in acetone at doses of 5 and 10 mg administered topically twice per week for 20 weeks induced skin tumors in transgenic Tg.AC mice. The clinical significance of this is unknown.

Carcinogenicity studies have been conducted with a gel formulation containing 1% clindamycin and 5% benzoyl peroxide. In a 2-year dermal carcinogenicity study in mice, treatment with the gel formulation at doses of 900, 2700, and 15000 mg/kg/day (1.8, 5.4, and 30 times the MRHD for clindamycin and 3.6, 10.8, and 60 times the MRHD for benzoyl peroxide, respectively, based on BSA comparisons) did not cause any increase in tumors. However, topical treatment with a different gel formulation containing 1% clindamycin and 5% benzoyl peroxide at doses of 100, 500, and 2000 mg/kg/day caused a dose-dependent increase in the incidence of keratoacanthoma at the treated skin site of male rats in a 2-year dermal carcinogenicity study in rats. In an oral (gavage) carcinogenicity study in rats, treatment with the gel formulation at doses of 300, 900, and 3000 mg/kg/day (1.2, 3.6, and 12 times the MRHD for clindamycin and 2.4, 7.2, and 24 times the MRHD for benzoyl peroxide, respectively, based on BSA comparisons) for up to 97 weeks did not cause any increase in tumors.

Clindamycin phosphate was not genotoxic in the human lymphocyte chromosome aberration assay. Benzoyl peroxide has been found to cause DNA strand breaks in a variety of mammalian cell types, to be mutagenic in S. typhimurium tests by some but not all investigators, and to cause sister chromatid exchanges in Chinese hamster ovary cells.

Fertility studies have not been performed with Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% or benzoyl peroxide, but fertility and mating ability have been studied with clindamycin. Fertility studies in rats treated orally with up to 300 mg/kg/day of clindamycin (approximately 120 times the MRHD for clindamycin, based on BSA comparisons) revealed no effects on fertility or mating ability.

14 CLINICAL STUDIES

The safety and efficacy of once daily use of clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% were assessed in two 12-week multi-center, randomized, blinded trials in subjects 12 years and older with moderate to severe acne vulgaris. The two trials were identical in design and compared clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% to clindamycin in the vehicle gel, benzoyl peroxide in the vehicle gel, and the vehicle gel alone.

The co-primary efficacy variables were:

(1) Mean absolute change from baseline at Week 12 in:

- Inflammatory lesion counts
- Non-inflammatory lesion counts

(2) Percent of subjects who had a 2-grade improvement from baseline on an Evaluator’s Global Severity (EGS) score.

The EGS scoring scale used in all of the clinical trials for clindamycin phosphate and benzoyl peroxide gel, 1.2%/2.5% is as follows:

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear</td>
<td>Normal, clear skin with no evidence of acne vulgaris</td>
</tr>
<tr>
<td>Almost Clear</td>
<td>Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must</td>
</tr>
</tbody>
</table>
be resolving and may be hyperpigmented, though not pink-red)

<table>
<thead>
<tr>
<th>category</th>
<th>description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulocystic lesions)</td>
</tr>
<tr>
<td>Moderate</td>
<td>Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one small nodulocystic lesion</td>
</tr>
<tr>
<td>Severe</td>
<td>Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be a few nodulocystic lesions</td>
</tr>
<tr>
<td>Very Severe</td>
<td>Highly inflammatory lesions predominate, variable number of comedones, many papules/pustules and many nodulocystic lesions</td>
</tr>
</tbody>
</table>

The results of Trial 1 at Week 12 are presented in Table 2:

**Table 2: Trial 1 Results**

<table>
<thead>
<tr>
<th></th>
<th>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% N=399</th>
<th>Clindamycin Gel N=408</th>
<th>Benzoyl Peroxide Gel N=408</th>
<th>Vehicle Gel N=201</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGSS Clear or Almost Clear</td>
<td>115 (29%)</td>
<td>84 (21%)</td>
<td>76 (19%)</td>
<td>29 (14%)</td>
</tr>
<tr>
<td>2-grade reduction from baseline</td>
<td>131 (33%)</td>
<td>100 (25%)</td>
<td>96 (24%)</td>
<td>38 (19%)</td>
</tr>
<tr>
<td>Inflammatory Lesions: Mean absolute change</td>
<td>14.8</td>
<td>12.2</td>
<td>13.0</td>
<td>9.0</td>
</tr>
<tr>
<td>Mean percent (%) reduction</td>
<td>55.0%</td>
<td>47.1%</td>
<td>49.3%</td>
<td>34.5%</td>
</tr>
<tr>
<td>Non-Inflammatory Lesions: Mean absolute change</td>
<td>22.1</td>
<td>17.9</td>
<td>20.6</td>
<td>13.2</td>
</tr>
<tr>
<td>Mean percent (%) reduction</td>
<td>45.3%</td>
<td>38.0%</td>
<td>40.2%</td>
<td>28.6%</td>
</tr>
</tbody>
</table>

The results of Trial 2 at Week 12 are presented in Table 3:

**Table 3: Trial 2 Results**

<table>
<thead>
<tr>
<th></th>
<th>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% N=398</th>
<th>Clindamycin Gel N=404</th>
<th>Benzoyl Peroxide Gel N=403</th>
<th>Vehicle Gel N=194</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGSS Clear or Almost Clear</td>
<td>113 (28%)</td>
<td>94 (23%)</td>
<td>94 (23%)</td>
<td>21 (11%)</td>
</tr>
<tr>
<td></td>
<td>147 (37%)</td>
<td>114 (28%)</td>
<td>114 (28%)</td>
<td>27 (14%)</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>2-grade reduction from baseline</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inflammatory Lesions:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean absolute change</td>
<td>13.7</td>
<td>11.3</td>
<td>11.2</td>
<td>5.7</td>
</tr>
<tr>
<td>Mean percent (%) reduction</td>
<td>54.2%</td>
<td>45.3%</td>
<td>45.7%</td>
<td>23.3%</td>
</tr>
<tr>
<td><strong>Non-Inflammatory Lesions:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean absolute change</td>
<td>19.0</td>
<td>14.9</td>
<td>15.2</td>
<td>8.3</td>
</tr>
<tr>
<td>Mean percent (%) reduction</td>
<td>41.2%</td>
<td>34.3%</td>
<td>34.5%</td>
<td>19.2%</td>
</tr>
</tbody>
</table>

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is a white to off-white smooth gel supplied as:

NDC 45802-597-01 50 g pump

16.2 Dispensing Instructions for the Pharmacist

- Dispense Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% with a 10-week expiration date.
- Specify “Store at room temperature up to 25°C (77°F). Do not freeze.”

16.3 Storage and Handling

- PHARMACIST: Prior to Dispensing: Store in a refrigerator, 2°C to 8°C (36°F to 46°F).
- PATIENT: Store at room temperature at or below 25°C (77°F).
- Protect from freezing.
- Store pump upright.
- Keep out of the reach of children.
- Keep container tightly closed.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

- Patients who develop allergic reactions such as severe swelling or shortness of breath should discontinue use and contact their physician immediately.
- Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% may cause irritation such as erythema, scaling, itching, or burning, especially when used in combination with other topical acne therapies.
- Excessive or prolonged exposure to sunlight should be limited. To minimize exposure to
PATIENT INFORMATION

Clindamycin Phosphate (klin-da-MYE-sin fos-fate) and Benzoyl Peroxide (BEN-zoe-il peer OKS-ide) Gel, 1.2%/2.5%

Important information: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is for use on skin only (topical use). Do not use Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% in your mouth, eyes, or vagina.

What is Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%?

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years of age and older.

It is not known if Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is safe and effective for use longer than 12 weeks.

It is not known if Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is safe and effective in children under 12 years of age.

Do not use Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% if you have:

• had an allergic reaction to clindamycin, benzoyl peroxide, lincomycin or any of the ingredients in Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%. See the end of this leaflet for a complete list of ingredients in Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%.
• Crohn’s disease or ulcerative colitis.
• had inflammation of the colon (colitis), or severe diarrhea with past antibiotic use.

Talk with your doctor if you are not sure if you have any of the conditions listed above.

Before using Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, tell your doctor about all of your medical conditions, including if you:

• plan to have surgery. Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% may affect how certain medicines work that may be given during surgery.
• are pregnant or plan to become pregnant. It is not known if Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% passes into your breast milk. Clindamycin when taken by mouth or by injection has been reported to appear in breast milk. Talk to your doctor about the best way to feed your baby during treatment with Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% may affect the way other medicines work and other medicines may affect how Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% works.

• Especially tell your doctor if you take medicine by mouth that contains erythromycin or use products on your skin that contain erythromycin. Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% should not be used with products that contain erythromycin.
• Tell your doctor about any skin products you use. Other skin and topical acne products may
Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

**How should I use Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%?**

- Use Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% exactly as your doctor tells you to use it. See the detailed “Instructions for Use” for directions about how to apply Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%.
- Your doctor will tell you how long to use Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%.
- Apply Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to your face 1 time each day.

**What should I avoid while using Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%?**

- Limit your time in sunlight. You should avoid using tanning beds or sunlamps during treatment with Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%. If you have to be in sunlight, wear a wide-brimmed hat or other protective clothing, and use sunscreen to cover the treated areas.
- Avoid getting Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% in your hair or on colored fabric. Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% may bleach hair or colored fabric.

**What are possible side effects of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%?**

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% can cause serious side effects including:

- **Inflammation of the colon (colitis).** Stop using Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% and call your doctor right away if you have severe stomach (abdominal) cramps, watery diarrhea, or bloody diarrhea during treatment, and within several weeks after treatment with Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%.

- **Allergic reactions.** Stop using Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, call your doctor and get help right away if you have any of the following symptoms during treatment with Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%:
  - severe itching
  - swelling of your face, eyes, lips, tongue or throat
  - trouble breathing

The most common side effects of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% include application site pain, application site irritation including redness, itching, burning, and stinging. Stop using Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% and call your doctor if you have a skin rash or your skin becomes very red, itchy or swollen. Talk to your doctor about any side effect that bothers you or that does not go away.

These are not all the possible side effects with Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088

**How should I store Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%?**
Keep Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% and all medicines out of the reach of children.

General information about the safe and effective use of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% for a condition for which it was not prescribed. Do not give Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to other people, even if they have the same condition you have. It may harm them. You can also ask your doctor or pharmacist for information about Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% that is written for healthcare professionals.

What are the ingredients in Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%?

Active Ingredients: clindamycin phosphate and benzoyl peroxide

Inactive Ingredients: purified water, carbomer 980, propylene glycol, and potassium hydroxide

This Patient Information has been approved by the U.S. Food and Drug Administration.

INSTRUCTIONS FOR USE

Clindamycin Phosphate (klin-da-MYE-sin fos-fate) and Benzoyl Peroxide (BEN-zoe-il peer-OKS-ide) Gel, 1.2%/2.5%

Important Information: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is for use on skin only (topical use). Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% is not for use in your mouth, eyes or vagina

Read this Instructions for Use before you start using Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.

• Apply Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to your face 1 time each day as prescribed.
• Before you apply Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, wash your face gently with a mild soap, rinse with warm water, and pat your skin dry.
• To apply Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to your face, use the pump to dispense one pea-sized amount of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% onto your fingertip. See Figure 1.
• One pea-sized amount of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% should be enough to cover your entire face.
Figure 1

- Dot the one pea-sized amount of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% onto six areas of your face (chin, left cheek, right cheek, nose, left forehead, right forehead). See Figure 2.
Spread the gel over your face and gently rub it in. It is important to spread the gel over your entire face. If your doctor tells you to put Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% on other areas of your skin with acne, be sure to ask how much you should use.

Wash your hands with soap and water after applying Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%.

How should I store Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%?

- Store Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% at room temperature at or below 77°F (25°C).
- Do not freeze Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%.
- Throw away (discard) Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% that has passed the expiration date.
- Store pump upright.
- Keep the container tightly closed.

Keep Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% and all medicines out of the reach of children.

The Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.

Made in Israel
Manufactured By Perrigo
Yeruham, Israel

Distributed By Perrigo
Allegan, MI 49010

www.perrigorx.com

Rev 07-20

Package/Label Display Panel- Carton

Rx Only

Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%

For Topical Use Only

One premixed 50-gram pump dispenser
# CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

**clindamycin phosphate, benzoyl peroxide gel**

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>TOPICAL</td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENZOYL PEROXIDE</td>
<td>BENZOYL PEROXIDE</td>
<td>25 mg in 1 g</td>
</tr>
<tr>
<td>CLINDAMYCIN PHOSPHATE</td>
<td>CLINDAMYCIN</td>
<td>10 mg in 1 g</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>WATER</td>
<td></td>
</tr>
<tr>
<td>CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED)</td>
<td></td>
</tr>
<tr>
<td>PROPYLENE GLYCOL</td>
<td></td>
</tr>
<tr>
<td>POTASSIUM HYDROXIDE</td>
<td></td>
</tr>
</tbody>
</table>

## Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>WHITE (White-to-off-white)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td></td>
</tr>
<tr>
<td>Flavor</td>
<td></td>
</tr>
</tbody>
</table>

**ATTENTION PHARMACIST:**
Prior to dispensing: Store in a refrigerator, 2°C to 8°C (36°F to 46°F). Do not freeze.

**Dispensing instructions:** Dispense Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% with a 10-week expiration date. Store at room temperature up to 25°C (77°F). Do not freeze.

Use by: __________

Use by date handwritten on your label or within 10 weeks of dispensing date.

**Usual dosage:** Apply once daily or as directed by physician. See package insert.

**Precautions:** For external use only. Avoid contact with eyes and mucous membranes. May bleach colored fabric or hair. Each gram of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, as dispensed, contains 10 mg (1%) clindamycin as phosphate and 25 mg (2.5%) benzoyl peroxide in a base of carbonar 980, propylene glycol, potassium hydroxide, and purified water. Store at room temperature at or below 25°C (77°F).

Do not freeze.

Made in Israel
Manufactured by Perrigo Yenaim, Israel
3611671 RC F1
Distributed by Perrigo
Allegan, MI 49010
www.perrigo.com
Rev 07-18
### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:45802-597-01</td>
<td>1 in 1 CARTON</td>
<td>09/12/2019</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>50 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA205397</td>
<td>09/12/2019</td>
<td></td>
</tr>
</tbody>
</table>

Labeler - Perrigo New York Inc (078846912)

Revised: 7/2020

Perrigo New York Inc